Viemed Healthcare (NASDAQ:VMD) Downgraded by TheStreet to “C+”

TheStreet downgraded shares of Viemed Healthcare (NASDAQ:VMD) from a b- rating to a c+ rating in a research report report published on Monday, TheStreetRatingsTable reports.

A number of other analysts have also recently issued reports on the stock. Acumen Capital reissued a buy rating and issued a C$14.00 price objective on shares of Viemed Healthcare in a research note on Friday, September 17th. Bloom Burton raised shares of Viemed Healthcare from an accumulate rating to a buy rating in a research note on Wednesday, August 4th. Finally, Zacks Investment Research cut shares of Viemed Healthcare from a buy rating to a hold rating in a research note on Thursday, August 26th. One equities research analyst has rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of Buy and a consensus target price of $11.50.

Shares of VMD stock opened at $6.10 on Monday. Viemed Healthcare has a 12 month low of $5.77 and a 12 month high of $10.96. The stock has a market cap of $242.60 million, a P/E ratio of 22.59 and a beta of 1.47. The company has a current ratio of 2.57, a quick ratio of 2.43 and a debt-to-equity ratio of 0.07. The company has a 50 day simple moving average of $6.26 and a two-hundred day simple moving average of $6.70.

Viemed Healthcare (NASDAQ:VMD) last announced its earnings results on Monday, August 2nd. The company reported $0.04 EPS for the quarter, beating the Zacks’ consensus estimate of $0.02 by $0.02. The business had revenue of $27.40 million during the quarter, compared to analysts’ expectations of $27.50 million. Viemed Healthcare had a net margin of 9.24% and a return on equity of 13.63%. As a group, equities analysts forecast that Viemed Healthcare will post 0.22 earnings per share for the current year.

Several large investors have recently modified their holdings of VMD. Nisa Investment Advisors LLC bought a new position in Viemed Healthcare during the second quarter valued at $56,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Viemed Healthcare by 135.0% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,259 shares of the company’s stock valued at $94,000 after purchasing an additional 5,319 shares during the last quarter. BCM Advisors LLC bought a new position in Viemed Healthcare during the second quarter valued at $70,000. Cambridge Investment Research Advisors Inc. bought a new position in Viemed Healthcare during the second quarter valued at $81,000. Finally, Ergoteles LLC bought a new position in Viemed Healthcare during the first quarter valued at $115,000. Hedge funds and other institutional investors own 56.43% of the company’s stock.

About Viemed Healthcare

Viemed Healthcare, Inc engages in the provision of home healthcare solutions. Through its subsidiaries, it supplies home medical equipment which provides post-acute respiratory services. It also offers respiratory disease management and in-home sleep testing and sleep apnea treatment. The company was founded by Casey Hoyt, Max Hoyt, and Michael Moore on December 14, 2016 and is headquartered in Lafayette, LA.

See Also: Blue-Chip Stocks

Receive News & Ratings for Viemed Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viemed Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.